SCL Group is poised to expand its Korean-style precision diagnosis and health screening model into Southeast Asia through a partnership with Indonesia’s National Hospital.
The company announced on April 24 that it will sign a memorandum of understanding (MOU) with RSCM, a national hospital under Indonesia’s Ministry of Health, in Jakarta on April 27.
RSCM Hospital, a leading national healthcare facility, treats over 1 million patients annually.
The collaboration will focus on early cancer screening, genetic testing, artificial intelligence (AI) driven early diagnosis solutions, shared use of medical equipment, and partnerships in healthcare and information technology (IT) sectors.
Indonesia, Southeast Asia’s most populous nation, is experiencing a growing demand for medical services and shows promising potential for growth in preventive medicine and precision diagnostics.
Recent diplomatic visits by the Indonesian president to South Korea have accelerated bilateral cooperation in the healthcare sector.
Lee Kyung-ryul, chairman of SCL Group, emphasized that it aims to strengthen the partnerships with local medical institutions, leveraging the extensive experience in diagnostic testing and health screenings. The goal is to promote and expand the K-healthcare model in the region.
SCL Group continues to bolster its position as a comprehensive healthcare conglomerate, with subsidiaries including SCL (Seoul Clinical Research Institute) and Hanaro Medical Foundation, which specialize in diagnostic testing and health screenings.
